Li Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Li Lin has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Wangjun Liao
Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China
3 shared publications Junhao Zhang
Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
2 shared publicationsMin Shi
Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
2 shared publicationsYantan Liu
Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
2 shared publicationsYulin Liao
Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
2 shared publicationsBingsheng Yang
Department of Orthopedics, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China
1 shared publication
Latest Publications
- Open Access
- 19 July 2023
- Published by Elsevier in Molecular Therapy
- Vol. 31  (9) , 2662-2680
Alcohol reshapes a liver premetastatic niche for cancer by extra- and intrahepatic crosstalk-mediated immune evasion
- 19 July 2023
- Published by Elsevier in Molecular Therapy
- Vol. 31  (9) , 2662-2680
Open AccessAlcohol reshapes a liver premetastatic niche for cancer by extra- and intrahepatic crosstalk-mediated immune evasion
- Open Access
- 6 September 2022
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 13, 949110
Development and validation of a novel cellular senescence-related prognostic signature for predicting the survival and immune landscape in hepatocellular carcinoma
Background: Cellular senescence is a typical irreversible form of life stagnation, and recent studies have suggested that long non-coding ribonucleic acids (lncRNA) regulate the occurrence and development of various tumors. In the present study, we attempted to construct a novel signature for predicting the survival of patients with hepatocellular carcinoma (HCC) and the associated immune landscape based on senescence-related (sr) lncRNAs.Method: Expression profiles of srlncRNAs in 424 patients with HCC were retrieved from The Cancer Genome Atlas database. Lasso and Cox regression analyses were performed to identify differentially expressed lncRNAs related to senescence. The prediction efficiency of the signature was checked using a receiver operating characteristic (ROC) curve, Kaplan–Meier analysis, Cox regression analyses, nomogram, and calibration. The risk groups of the gene set enrichment analysis, immune analysis, and prediction of the half-maximal inhibitory concentration (IC50) were also analyzed. Quantitative real-time polymerase chain reaction (qPCR) was used to confirm the levels of AC026412.3, AL451069.3, and AL031985.3 in normal hepatic and HCC cell lines.Results: We identified 3 srlncRNAs (AC026412.3, AL451069.3, and AL031985.3) and constructed a new risk model. The results of the ROC curve and Kaplan–Meier analysis suggested that it was concordant with the prediction. Furthermore, a nomogram model was constructed to accurately predict patient prognosis. The risk score also correlated with immune cell infiltration status, immune checkpoint expression, and chemosensitivity. The results of qPCR revealed that AC026412.3 and AL451069.3 were significantly upregulated in hepatoma cell lines.Conclusion: The novel srlncRNA (AC026412.3, AL451069.3, and AL031985.3) signatures may provide insights into new therapies and prognosis predictions for patients with HCC.
- 6 September 2022
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 13, 949110
Open AccessDevelopment and validation of a novel cellular senescence-related prognostic signature for predicting the survival and immune landscape in hepatocellular carcinoma
Background: Cellular senescence is a typical irreversible form of life stagnation, and recent studies have suggested that long non-coding ribonucleic acids (lncRNA) regulate the occurrence and development of various tumors. In the present study, we attempted to construct a novel signature for predicting the survival of patients with hepatocellular carcinoma (HCC) and the associated immune landscape based on senescence-related (sr) lncRNAs.Method: Expression profiles of srlncRNAs in 424 patients with HCC were retrieved from The Cancer Genome Atlas database. Lasso and Cox regression analyses were performed to identify differentially expressed lncRNAs related to senescence. The prediction efficiency of the signature was checked using a receiver operating characteristic (ROC) curve, Kaplan–Meier analysis, Cox regression analyses, nomogram, and calibration. The risk groups of the gene set enrichment analysis, immune analysis, and prediction of the half-maximal inhibitory concentration (IC50) were also analyzed. Quantitative real-time polymerase chain reaction (qPCR) was used to confirm the levels of AC026412.3, AL451069.3, and AL031985.3 in normal hepatic and HCC cell lines.Results: We identified 3 srlncRNAs (AC026412.3, AL451069.3, and AL031985.3) and constructed a new risk model. The results of the ROC curve and Kaplan–Meier analysis suggested that it was concordant with the prediction. Furthermore, a nomogram model was constructed to accurately predict patient prognosis. The risk score also correlated with immune cell infiltration status, immune checkpoint expression, and chemosensitivity. The results of qPCR revealed that AC026412.3 and AL451069.3 were significantly upregulated in hepatoma cell lines.Conclusion: The novel srlncRNA (AC026412.3, AL451069.3, and AL031985.3) signatures may provide insights into new therapies and prognosis predictions for patients with HCC.
- 30 September 2021
- Published by JCFCorp SG PTE LTD in Tobacco Regulatory Science
- Vol. 7  (5) , 1551-1557
Efficacy of Shenqi Runchang Tongbian Decoction in Treatment of Children with Constipation and Its Effect on Clinical Symptoms of Children
To investigate the efficacy of Shenqi Runchang Tongbian Decoction in the treatment of children with constipation and its effect on the clinical symptoms of children. Methods: From January 2016 to January 2020, 100 patients with constipation were randomly divided into two groups. The control group was treated with lactulose oral solution, and the study group was treated with Shenqi Runchang Tongbian Decoction. Both groups were administered with drugs for 14 days, and the two groups were followed up on the 28th day. The effectiveness of the two groups was compared before treatment and during follow-up. The changes of various symptom scores were compared before treatment, after treatment and during follow-up, and the changes of primary symptom score, secondary symptom score and total score were compared before treatment, after treatment and during follow-up. Results: After treatment, the effectiveness of the study group was higher than that of the control group at follow-up (P 0.05). There was no significant difference in the scores of facial color, lips, sleep, urination and hand-foot-heart-chest symptoms before treatment and during follow-up between the control group and the study group (P > 0.05). The scores of lip symptoms after treatment in the study group were lower than those in the control group (P < 0.05). The scores of appetites, halitosis, abdominal distension and abdominal pain, defecation duration, defecation difficulty, defecation frequency, stool property after treatment and during follow-up in the study group were lower than those in the control group (P <0.05). The total score, the secondary symptom score and the primary symptom score of the two groups before treatment and during follow-up were lower than those before treatment (P < 0.05). The total score, the secondary symptom score and the primary symptom score in the study group were lower than those in the control group after treatment and during follow-up (P < 0.05). Conclusion: The treatment of children with constipation with Shenqi Runchang Tongbian Decoction can improve the secondary symptoms and primary symptoms of children and improve the comprehensive curative effect, especially in the aspects of improving appetite, halitosis, abdominal distension and abdominal pain, defecation duration, defecation difficulty, defecation frequency and stool property. It can effectively enhance the gastrointestinal function and promote the rehabilitation of children. It is worthy of being popularized in clinical practice.
- 30 September 2021
- Published by JCFCorp SG PTE LTD in Tobacco Regulatory Science
- Vol. 7  (5) , 1551-1557
Efficacy of Shenqi Runchang Tongbian Decoction in Treatment of Children with Constipation and Its Effect on Clinical Symptoms of Children
To investigate the efficacy of Shenqi Runchang Tongbian Decoction in the treatment of children with constipation and its effect on the clinical symptoms of children. Methods: From January 2016 to January 2020, 100 patients with constipation were randomly divided into two groups. The control group was treated with lactulose oral solution, and the study group was treated with Shenqi Runchang Tongbian Decoction. Both groups were administered with drugs for 14 days, and the two groups were followed up on the 28th day. The effectiveness of the two groups was compared before treatment and during follow-up. The changes of various symptom scores were compared before treatment, after treatment and during follow-up, and the changes of primary symptom score, secondary symptom score and total score were compared before treatment, after treatment and during follow-up. Results: After treatment, the effectiveness of the study group was higher than that of the control group at follow-up (P 0.05). There was no significant difference in the scores of facial color, lips, sleep, urination and hand-foot-heart-chest symptoms before treatment and during follow-up between the control group and the study group (P > 0.05). The scores of lip symptoms after treatment in the study group were lower than those in the control group (P < 0.05). The scores of appetites, halitosis, abdominal distension and abdominal pain, defecation duration, defecation difficulty, defecation frequency, stool property after treatment and during follow-up in the study group were lower than those in the control group (P <0.05). The total score, the secondary symptom score and the primary symptom score of the two groups before treatment and during follow-up were lower than those before treatment (P < 0.05). The total score, the secondary symptom score and the primary symptom score in the study group were lower than those in the control group after treatment and during follow-up (P < 0.05). Conclusion: The treatment of children with constipation with Shenqi Runchang Tongbian Decoction can improve the secondary symptoms and primary symptoms of children and improve the comprehensive curative effect, especially in the aspects of improving appetite, halitosis, abdominal distension and abdominal pain, defecation duration, defecation difficulty, defecation frequency and stool property. It can effectively enhance the gastrointestinal function and promote the rehabilitation of children. It is worthy of being popularized in clinical practice.
- Open Access
- 30 January 2021
- Published by Wiley in Journal of Oncology
- Vol. 2021, 1-16
Identification and Analysis of Three Hub Prognostic Genes Related to Osteosarcoma Metastasis
Osteosarcoma (OS) often occurs in children and often undergoes metastasis, resulting in lower survival rates. Information on the complexity and pathogenic mechanism of OS is limited, and thus, the development of treatments involving alternative molecular and genetic targets is hampered. We categorized transcriptome data into metastasis and nonmetastasis groups, and 400 differential RNAs (230 messenger RNAs (mRNAs) and 170 long noncoding RNAs (lncRNAs)) were obtained by the edgeR package. Prognostic genes were identified by performing univariate Cox regression analysis and the Kaplan–Meier (KM) survival analysis. We then examined the correlation between the expression level of prognostic lncRNAs and mRNAs. Furthermore, microRNAs (miRNAs) corresponding to the coexpression of lncRNA-mRNA was predicted, which was used to construct a competitive endogenous RNA (ceRNA) regulatory network. Finally, multivariate Cox proportional risk regression analysis was used to identify hub prognostic genes. Three hub prognostic genes (ABCG8, LOXL4, and PDE1B) were identified as potential prognostic biomarkers and therapeutic targets for OS. Furthermore, transcriptions factors (TFs) (DBP, ESX1, FOS, FOXI1, MEF2C, NFE2, and OTX2) and lncRNAs (RP11-357H14.16, RP11-284N8.3, and RP11-629G13.1) that were able to affect the expression levels of genes before and after transcription were found to regulate the prognostic hub genes. In addition, we identified drugs related to the prognostic hub genes, which may have potential clinical applications. Immunohistochemistry (IHC) and quantitative real-time polymerase chain reaction (qRT-PCR) confirmed that the expression levels of ABCG8, LOXL4, and PDE1B coincided with the results of bioinformatics analysis. Moreover, the relationship between the hub prognostic gene expression and patient prognosis was also validated. Our study elucidated the roles of three novel prognostic biomarkers in the pathogenesis of OS as well as presenting a potential clinical treatment for OS.
- 30 January 2021
- Published by Wiley in Journal of Oncology
- Vol. 2021, 1-16
Open AccessIdentification and Analysis of Three Hub Prognostic Genes Related to Osteosarcoma Metastasis
Osteosarcoma (OS) often occurs in children and often undergoes metastasis, resulting in lower survival rates. Information on the complexity and pathogenic mechanism of OS is limited, and thus, the development of treatments involving alternative molecular and genetic targets is hampered. We categorized transcriptome data into metastasis and nonmetastasis groups, and 400 differential RNAs (230 messenger RNAs (mRNAs) and 170 long noncoding RNAs (lncRNAs)) were obtained by the edgeR package. Prognostic genes were identified by performing univariate Cox regression analysis and the Kaplan–Meier (KM) survival analysis. We then examined the correlation between the expression level of prognostic lncRNAs and mRNAs. Furthermore, microRNAs (miRNAs) corresponding to the coexpression of lncRNA-mRNA was predicted, which was used to construct a competitive endogenous RNA (ceRNA) regulatory network. Finally, multivariate Cox proportional risk regression analysis was used to identify hub prognostic genes. Three hub prognostic genes (ABCG8, LOXL4, and PDE1B) were identified as potential prognostic biomarkers and therapeutic targets for OS. Furthermore, transcriptions factors (TFs) (DBP, ESX1, FOS, FOXI1, MEF2C, NFE2, and OTX2) and lncRNAs (RP11-357H14.16, RP11-284N8.3, and RP11-629G13.1) that were able to affect the expression levels of genes before and after transcription were found to regulate the prognostic hub genes. In addition, we identified drugs related to the prognostic hub genes, which may have potential clinical applications. Immunohistochemistry (IHC) and quantitative real-time polymerase chain reaction (qRT-PCR) confirmed that the expression levels of ABCG8, LOXL4, and PDE1B coincided with the results of bioinformatics analysis. Moreover, the relationship between the hub prognostic gene expression and patient prognosis was also validated. Our study elucidated the roles of three novel prognostic biomarkers in the pathogenesis of OS as well as presenting a potential clinical treatment for OS.
- Open Access
- 20 February 2019
- Published by Springer Nature in Cell Death & Disease
- Vol. 10  (3) , 1-13
ATXN2L upregulated by epidermal growth factor promotes gastric cancer cell invasiveness and oxaliplatin resistance
For gastric cancer (GC) control, metastasis and chemoresistance are the major challenges, accompanied with various stresses. Ataxin-2-like (ATXN2L) was discovered as a novel regulator of stress granules, yet its function in cancers remained unknown. Hence, we wanted to explore the functions of ATXN2L to see whether it participates in stress-related cancer malignant activities. Clinical follow-up was performed to see the impact of ATXN2L on GC patient survival. As a result, ATXN2L expression was upregulated in GC tissue and indicated adverse prognosis for overall survival and recurrence. In GC cells, ATXN2L expression was knocked down and functional experiments were performed. ATXN2L promoted GC cell migration and invasion via epithelial to mesenchymal transition, yet no influence on proliferation was detected by ATXN2L interference. When adding the chemotherapeutic agent oxaliplatin to induce stress, silencing ATXN2L sensitized GC cells to oxaliplatin. Interestingly, oxaliplatin was found to in turn promote ATXN2L expression and stress granule assembly. Then, two acquired oxaliplatin-resistant strains were generated by long-term oxaliplatin induction. The oxaliplatin-resistant strains presented with elevated ATXN2L levels, while silencing ATXN2L in the strains reversed the oxaliplatin resistance by increasing reactive oxygen species production and apoptosis. These results suggested that ATXN2L was responsible for not only intrinsic but also acquired oxaliplatin chemoresistance. Finally, ATXN2L-related signaling was screened using bioinformatic methods, and epidermal growth factor (EGF) was verified to promote ATXN2L expression via PI3K/Akt signaling activation. Blocking EGFR/ATXN2L signaling reversed GC cell oxaliplatin resistance and inhibited migration. In conclusion, ATXN2L promotes cell invasiveness and oxaliplatin resistance and can be upregulated by EGF via PI3K/Akt signaling. ATXN2L may be an indicator and therapeutic target in GC, especially for oxaliplatin-based chemotherapy.
- 20 February 2019
- Published by Springer Nature in Cell Death & Disease
- Vol. 10  (3) , 1-13
Open AccessATXN2L upregulated by epidermal growth factor promotes gastric cancer cell invasiveness and oxaliplatin resistance
For gastric cancer (GC) control, metastasis and chemoresistance are the major challenges, accompanied with various stresses. Ataxin-2-like (ATXN2L) was discovered as a novel regulator of stress granules, yet its function in cancers remained unknown. Hence, we wanted to explore the functions of ATXN2L to see whether it participates in stress-related cancer malignant activities. Clinical follow-up was performed to see the impact of ATXN2L on GC patient survival. As a result, ATXN2L expression was upregulated in GC tissue and indicated adverse prognosis for overall survival and recurrence. In GC cells, ATXN2L expression was knocked down and functional experiments were performed. ATXN2L promoted GC cell migration and invasion via epithelial to mesenchymal transition, yet no influence on proliferation was detected by ATXN2L interference. When adding the chemotherapeutic agent oxaliplatin to induce stress, silencing ATXN2L sensitized GC cells to oxaliplatin. Interestingly, oxaliplatin was found to in turn promote ATXN2L expression and stress granule assembly. Then, two acquired oxaliplatin-resistant strains were generated by long-term oxaliplatin induction. The oxaliplatin-resistant strains presented with elevated ATXN2L levels, while silencing ATXN2L in the strains reversed the oxaliplatin resistance by increasing reactive oxygen species production and apoptosis. These results suggested that ATXN2L was responsible for not only intrinsic but also acquired oxaliplatin chemoresistance. Finally, ATXN2L-related signaling was screened using bioinformatic methods, and epidermal growth factor (EGF) was verified to promote ATXN2L expression via PI3K/Akt signaling activation. Blocking EGFR/ATXN2L signaling reversed GC cell oxaliplatin resistance and inhibited migration. In conclusion, ATXN2L promotes cell invasiveness and oxaliplatin resistance and can be upregulated by EGF via PI3K/Akt signaling. ATXN2L may be an indicator and therapeutic target in GC, especially for oxaliplatin-based chemotherapy.
- Open Access
- 2 May 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18  (1) , 1-9
Combined neutrophil/platelet/lymphocyte/differentiation score predicts chemosensitivity in advanced gastric cancer
Gastric cancer is common in developing regions, and we hope to find out an economical but practical prognostic indicator. It was reported that pre-treatment peripheral neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR), as well as differentiation status, were associated with cancer progression. Hence, we introduced a novel combined Neutrophil/platelet/lymphocyte/differentiation Score (cNPLDS) to improve the prediction value of palliative chemotherapeutic response in advanced gastric cancer. According to statistical sample size estimation, 136 primary diagnosed unresectable advanced ptaients were included for a retrospective study. The follow-up end-point was progression free survival (PFS) during the first-line palliative chemotherapy. Differentiation stratified patients into well, medium and poor groups by score 1 to 3, while patients with neither elevated NLR and PLR, only one elevated, or both elevated were of the combined NLR-PLR score (cNPS) 1 to 3, respectively. The cNPLDS was calculated by multiplying the tumor differentiation score and cNPS. Determined by the receiver operating characteristic (ROC) curve, the optimal cut-off points for NLR and PLR were 3.04 and 223. Through univariate analysis and survival analysis, poor differentiation, high NLR, high PLR, high cNPS, and high cNPLDS respectively indicated inferior PFS during the first-line palliative chemotherapy. Patients were furhter classified into low to high risk groups by cNPLDS. Groups of elevated NLR, PLR, cNPS, and cNPLDS showed lower disease control rate. Compared to other parameters, cNPLDS significantly improved the accuracy in predicing the first-progression. This study indicates that the novel parameter cNPLDS is superior to NLR or PLR alone, or even cNPS, in predicting the first-line chemosensitivity in advanced gastric cancer.
- 2 May 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18  (1) , 1-9
Open AccessCombined neutrophil/platelet/lymphocyte/differentiation score predicts chemosensitivity in advanced gastric cancer
Gastric cancer is common in developing regions, and we hope to find out an economical but practical prognostic indicator. It was reported that pre-treatment peripheral neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR), as well as differentiation status, were associated with cancer progression. Hence, we introduced a novel combined Neutrophil/platelet/lymphocyte/differentiation Score (cNPLDS) to improve the prediction value of palliative chemotherapeutic response in advanced gastric cancer. According to statistical sample size estimation, 136 primary diagnosed unresectable advanced ptaients were included for a retrospective study. The follow-up end-point was progression free survival (PFS) during the first-line palliative chemotherapy. Differentiation stratified patients into well, medium and poor groups by score 1 to 3, while patients with neither elevated NLR and PLR, only one elevated, or both elevated were of the combined NLR-PLR score (cNPS) 1 to 3, respectively. The cNPLDS was calculated by multiplying the tumor differentiation score and cNPS. Determined by the receiver operating characteristic (ROC) curve, the optimal cut-off points for NLR and PLR were 3.04 and 223. Through univariate analysis and survival analysis, poor differentiation, high NLR, high PLR, high cNPS, and high cNPLDS respectively indicated inferior PFS during the first-line palliative chemotherapy. Patients were furhter classified into low to high risk groups by cNPLDS. Groups of elevated NLR, PLR, cNPS, and cNPLDS showed lower disease control rate. Compared to other parameters, cNPLDS significantly improved the accuracy in predicing the first-progression. This study indicates that the novel parameter cNPLDS is superior to NLR or PLR alone, or even cNPS, in predicting the first-line chemosensitivity in advanced gastric cancer.
- 21 July 2014
- Published by Springer Nature in Oncogene
- Vol. 34  (21) , 2700-2710
MACC1 supports human gastric cancer growth under metabolic stress by enhancing the Warburg effect
Cancer cells mainly metabolize by glycolysis (the Warburg effect) and are better adapted to resist metabolic stress. Metastasis-associated in colon cancer-1 (MACC1) is an oncogene promoting gastric cancer (GC) growth and metastasis, and its expression positively correlates with GC progression. However, it is unknown why MACC1 elevates with GC progression and what is its role in cancer metabolism. In this study, we discovered that MACC1 expression was significantly upregulated via adenosine monophosphate-activated protein kinase signaling in response to glucose deprivation-induced metabolic stress. Clinical observation demonstrates that MACC1 expression was higher in advanced stage GC. MACC1 expression was proved to be positively correlated with the maximum standardized uptake value of 18F-deoxyglucose in the patients, and MACC1 enhanced 18F-deoxyglucose uptake in GC cells and the xenografts. The underlying mechanism was that MACC1 promoted the Warburg effect by upregulating the activities and expressions of a series of glycolytic enzymes, including hexokinase, pyruvate dehydrogenase kinase and lactate dehydrogenase, in GC cells. This metabolic shift enhanced cell viability and resistance to apoptosis by facilitating ATP generation, reducing the reactive oxygen species production and stabilizing the mitochondrial membrane potential. In contrast, MACC1-silenced or the Warburg effect-blocked GC cells were more vulnerable to metabolic stress. In conclusion, metabolic stress is one of the mechanisms that elevate MACC1 expression in GC, and MACC1 upregulation compensatively ensures GC growth against metabolic stress by facilitating the Warburg effect.
- 21 July 2014
- Published by Springer Nature in Oncogene
- Vol. 34  (21) , 2700-2710
MACC1 supports human gastric cancer growth under metabolic stress by enhancing the Warburg effect
Cancer cells mainly metabolize by glycolysis (the Warburg effect) and are better adapted to resist metabolic stress. Metastasis-associated in colon cancer-1 (MACC1) is an oncogene promoting gastric cancer (GC) growth and metastasis, and its expression positively correlates with GC progression. However, it is unknown why MACC1 elevates with GC progression and what is its role in cancer metabolism. In this study, we discovered that MACC1 expression was significantly upregulated via adenosine monophosphate-activated protein kinase signaling in response to glucose deprivation-induced metabolic stress. Clinical observation demonstrates that MACC1 expression was higher in advanced stage GC. MACC1 expression was proved to be positively correlated with the maximum standardized uptake value of 18F-deoxyglucose in the patients, and MACC1 enhanced 18F-deoxyglucose uptake in GC cells and the xenografts. The underlying mechanism was that MACC1 promoted the Warburg effect by upregulating the activities and expressions of a series of glycolytic enzymes, including hexokinase, pyruvate dehydrogenase kinase and lactate dehydrogenase, in GC cells. This metabolic shift enhanced cell viability and resistance to apoptosis by facilitating ATP generation, reducing the reactive oxygen species production and stabilizing the mitochondrial membrane potential. In contrast, MACC1-silenced or the Warburg effect-blocked GC cells were more vulnerable to metabolic stress. In conclusion, metabolic stress is one of the mechanisms that elevate MACC1 expression in GC, and MACC1 upregulation compensatively ensures GC growth against metabolic stress by facilitating the Warburg effect.
- Open Access
- 1 August 2003
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 278  (34) , 31479-31485
Stability of the Rel Homology Domain Is Critical for Generation of NF-κB p50 Subunit
- 1 August 2003
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 278  (34) , 31479-31485
Open AccessStability of the Rel Homology Domain Is Critical for Generation of NF-κB p50 Subunit